[Pubmed] Efficacy of Innovative Therapies in Myasthenia Gravis: Systematic Review, Meta-Analysis and Network Meta-Analys

[RSS-Bot]

Eur J Neurol. 2023 May 19. doi: 10.1111/ene.15872. Online ahead of print.

ABSTRACT

INTRODUCTION: Therapy of Myasthenia Gravis (MG) is undergoing a profound change with new treatments being tested. These include complement inhibitors and neonatal Fc receptor (FcRn) blockers. Objective of the study was to perform a meta-analysis and network meta-analysis of randomized and placebo-controlled trials of innovative therapies in MG with available efficacy data.

METHODS: We assessed statistical heterogeneity across trials with Cochrane Q test and I2 values. We pooled mean differences with the random effect model. We derived treatment efficacy after 26 weeks of treatment with Eculizumab and Ravulizumab, 28 days with Efgartigimod, 43 days with Rozanolixizumab, 12 weeks with Zilucoplan, and after 16, 24 or 52 weeks with Rituximab.

RESULTS: We observed an overall mean MG-ADL change of -2.17 points (95% CI -2.67, -1.67; p

Source: https://pubmed.ncbi.nlm.nih.gov/3720403 ... t6+86293ac